Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $39,621.45 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 1,947 shares of the business’s stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $20.35, for a total value of $39,621.45. Following the completion of the transaction, the insider now directly owns 65,418 shares in the company, valued at $1,331,256.30. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Castle Biosciences Price Performance

Shares of NASDAQ:CSTL traded down $0.14 during trading on Wednesday, hitting $18.80. 52,957 shares of the company were exchanged, compared to its average volume of 237,487. The company has a market cap of $516.06 million, a PE ratio of -8.77 and a beta of 0.93. The stock has a 50 day moving average of $21.81 and a 200 day moving average of $19.83. Castle Biosciences, Inc. has a 52-week low of $9.26 and a 52-week high of $26.70.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Wednesday, February 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.74. The firm had revenue of $66.12 million for the quarter, compared to the consensus estimate of $51.32 million. Castle Biosciences had a negative return on equity of 14.92% and a negative net margin of 26.15%. Sell-side analysts forecast that Castle Biosciences, Inc. will post -2.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CSTL shares. KeyCorp upped their price target on Castle Biosciences from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday, March 1st. Scotiabank upped their target price on Castle Biosciences from $33.00 to $37.00 and gave the company a “sector outperform” rating in a report on Friday, March 1st.

Institutional Investors Weigh In On Castle Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP raised its position in Castle Biosciences by 27.6% during the third quarter. GSA Capital Partners LLP now owns 52,195 shares of the company’s stock valued at $882,000 after purchasing an additional 11,280 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Castle Biosciences in the third quarter worth about $2,885,000. Deerfield Management Company L.P. Series C bought a new stake in shares of Castle Biosciences in the third quarter worth about $15,988,000. Schonfeld Strategic Advisors LLC grew its stake in shares of Castle Biosciences by 294.4% in the third quarter. Schonfeld Strategic Advisors LLC now owns 148,030 shares of the company’s stock worth $2,500,000 after purchasing an additional 110,500 shares during the last quarter. Finally, Millrace Asset Group Inc. bought a new stake in shares of Castle Biosciences in the third quarter worth about $1,306,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.